The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Hyperthermic intraperitoneal chemotherapy in platinum-sensitive relapsed epithelial ovarian cancer: The CHIPOR randomized phase III trial.
 
Jean-Marc Classe
Employment - Roche (I)
Consulting or Advisory Role - AstraZeneca; GlaxoSmithKline; Lilly O.; Myriad Genetic Laboratories
 
Pierre Meeus
No Relationships to Disclose
 
Eric Leblanc
No Relationships to Disclose
 
Romuald Wernert
No Relationships to Disclose
 
Francois Quenet
Honoraria - Ethicon; Gamida Cell; Sanofi
Consulting or Advisory Role - Gamida Cell
Travel, Accommodations, Expenses - Ethicon; Gamida Cell; Sanofi
 
Frédéric Marchal
No Relationships to Disclose
 
Gilles Houvenaeghel
No Relationships to Disclose
 
Anne-Sophie Bats
No Relationships to Disclose
 
Gwenael Ferron
Consulting or Advisory Role - AstraZeneca; GlaxoSmithKline/Tesaro; Rand Biotech
Travel, Accommodations, Expenses - AstraZeneca; Eisai/MSD; GlaxoSmithKline; PharmaMar; Rand Italy; Roche Pharma AG
 
Cecile Brigand
No Relationships to Disclose
 
Dominique Berton
No Relationships to Disclose
 
Laurence Gladieff
Honoraria - AstraZeneca (Inst); GlaxoSmithKline (Inst); MSD (Inst)
Consulting or Advisory Role - AstraZeneca (Inst); GlaxoSmithKline (Inst); MSD (Inst)
Travel, Accommodations, Expenses - AstraZeneca; MSD
 
Florence Joly
Consulting or Advisory Role - 3A Pharmaceuticals & Diagnostics; Amgen; Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Clovis Oncology; Eisai; GlaxoSmithKline; Ipsen; Janssen; MSD Oncology; Pfizer; Seagen
Travel, Accommodations, Expenses - AstraZeneca; BMS; Eisai; GlaxoSmithKline; Ipsen; Janssen; MSD Oncology
 
Isabelle Laure Ray-Coquard
Honoraria - Abbvie; Advaxis; AGENUS; Amgen; AstraZeneca; Bristol-Myers Squibb; Clovis Oncology; Daiichi Sankyo; DECIPHERA; Genmab; GlaxoSmithKline; Macrogenics; MERSANA; MSD Oncology; Novartis; OxOnc; Pfizer; PharmaMar; Roche; Seagen; Sutro Biopharma; Tesaro
Consulting or Advisory Role - Abbvie; AGENUS; AstraZeneca; Blueprint Medicines; BMS; Bristol-Myers Squibb; Clovis Oncology; Daichi; Deciphera; Eisai; Genmab; GlaxoSmithKline; Macrogenics; Mersana; MSD Oncology; Novartis; Novocure; Ose pharma; Pfizer; PharmaMar; Roche; Seagen; Sutro Biopharma; Tesaro
Research Funding - BMS; MSD Oncology; Roche/Genentech (Inst)
Travel, Accommodations, Expenses - Advaxis; AstraZeneca; BMS; Clovis Oncology; Clovis Oncology; GlaxoSmithKline; PharmaMar; Roche; Tesaro
(OPTIONAL) Uncompensated Relationships - Arcagy-Gineco; Belgium health authorities; French National Cancer Institute (INCA); GERMAN health authorities; ITALIAN HEALTH AUTORITIES
 
Sylvaine Durand-Fontanier
No Relationships to Disclose
 
Gabriel Liberale
No Relationships to Disclose
 
Emilie Brument
No Relationships to Disclose
 
Bernard Asselain
Honoraria - AstraZeneca; Bristol-Myers Squibb; Daiichi Sankyo Pharmaceutical; Gilead Sciences; Pierre Fabre; Roche; SERVIER
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Daiichi Sankyo Pharmaceutical; Gilead Sciences; Pierre Fabre; Roche; SERVIER
 
Loic Campion
No Relationships to Disclose
 
Olivier Glehen
Consulting or Advisory Role - Gamida Cell